08:30 - 08:35 |
Welcome speech
|
Prof. Hans Helge Seifert |
08:35 - 08:45 |
Introduction
|
PD Dr. Ashkan Mortezavi |
  |
Chair: Prof. Lukas Bubendorf
|
|
08:45 - 09:15 |
Molecularly-driven selection of systemic therapy - The ProBio trial
|
Prof. Henrik Grönberg (Krolinska Institutet, Sweden) |
09:15 - 09:45 |
Drivers of prostate cancer progression and drug resistance
|
Prof. Mark A. Rubin (Universität Bern, Switzerland) |
09:45 - 10:15 |
From tissue to liquid biopsies - insights and technical challenges
|
Johan Lindberg, PhD (Karolinska Institutet, Sweden) |
10:15 - 10:45 |
Coffee break
|
|
  |
Chair: Prof. Cyrill Rentsch
|
|
10:45 - 11:15 |
Epignomic features of circulating tumour DNA in metastatic prostate cancer
|
Dr. Alexander Wyatt (Vancouver Prostate Centre Canada) |
11:15 - 11:45 |
The role of circulating tumor cells in the metastatic process
|
Prof. Nicola Aceto (ETH, Switzerland) |
11:45 - 12:15 |
Novel drivers of castration-resistant prostate cancer
|
Prof. Andrea Alimonti (ETH, Switzerland) |
12:15 - 13:15 |
Lunch
|
|
  |
Chair: Prof. Frank Stenner
|
|
13:15 - 13:45 |
From biology to therapy in advanced prostate cancer
|
Prof. Johann de Bono (The Institute of Cancer Research, UK) |
13:45 - 14:15 |
Platform trials and adaptive randomization - statistical challenges in prostate cancer trials
|
Prof. Martin Eklund (Karolinska Institutet, Sweden) |
14:15 - 14:45 |
Patient selection for metastasis directed therapy and Lutetium- 177
|
Prof. Piet Ost (Ghent University, Belgium) |
14:45 - 15:15 |
Coffee Break
|
|
  |
Chair: Dr. Alexandros Papachristofilou
|
|
15:15 - 15:45 |
Sequencing, combining, re-challenging: the evolving therapeutic landscape for advanced prostate cancer
|
Bram de Laere, PhD (Ghent University, Belgium) |
15:45 - 16:15 |
Patient-derived organoids to test drug response and investigate drug resistance mechanisms in prostate cancer
|
Clémentine Le Magnen, PhD (universitätsspital basel, Switzerland) |
16:15 - 16:30 |
Summery and closing remarks
|
PD Dr. Ashkan Mortezavi |